MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial Of Its New Dual-Layer Stent For Cerebral Aneurysm Flow DiversionJuly 22, 2013 10:00 am | by The Associated Press | News | Comments
MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced earlier last week that they successfully completed their first enrollment in a multi-center, prospective, pivotal U.S. clinical trial to demonstrate the safety and efficacy of its FREDT flow diversion system (FREDT-Flow Re-Direction Endoluminal Device) for treating intracranial aneurysms.
San Diego sleep and respiratory medical devices maker ResMed notched a win, of sorts, against Taiwan's Apex Medical after the International Trade Commission ordered a consent decree banning Apex from importing into the U.S. products that infringe on ResMed's patents.
IPG, the leading nationwide provider of Implantable Device Benefit Management (DBM) solutions, was named a recipient of the 2013 CIO 100. The 26th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT).
Biosan Medical Receives U.S. Patent for Its Novel Device and Method of Treating the Deadliest Type of Stroke, Subarachnoid Hemorrhage (SAH), and Alzheimer’s DiseaseJuly 22, 2013 9:24 am | by Business Wire | News | Comments
Biosan Medical, an emerging medical device company, announced today that it has been issued U.S. Provisional Patent No. 61,957,293 for its revolutionary Ventritek105® Stroke Treatment Device and Method (“Device & method for CSF auto-transfusion therapy for the treatment of SAH (subarachnoid hemorrhage), Alzheimer’s Disease & other Neuro-Degenerative CNS diseases”).
Zynex Signs Strategic Agreement With Advanced Brain Monitoring, Expands Presence in Sleep Diagnostic MarketJuly 22, 2013 8:00 am | by The Associated Press | News | Comments
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnostics and cardiac monitoring, announces that it signed a strategic sales, marketing and distribution agreement with California based Advanced Brain Monitoring.
Massachusetts medical device giant Boston Scientific announced the start of a new clinical trial to evaluate the use of neurostimulation in treatment of chronic migraines. Boston Scientific's OPTIMISE trial is a randomized, placebo-controlled study assessing occipital nerve stimulation as a novel approach to treating migraines by masking the pain.
House GOP-ers are looking to rewrite the so-called "doc fix," replacing Medicare's sustainable growth rate fomula with a physician performance incentive program. The 70-page proposal claims to improve quality and efficiency in the healthcare system with a physician reimbursement system that would start with 5 years of consistent Medicare payments.
Paragonix Technologies Inc., Announces Publication by the ASAIO (American Society for Artificial Internal Organs) Journal of "Oxygen Consumption During Oxygenated Hypothermic Perfusion as a Measure of Donor Organ Viability"July 22, 2013 6:00 am | by The Associated Press | News | Comments
Paragonix Technologies, Inc. today announced that the American Society for Artificial Internal Organs (ASAIO) Journal has published an original research paper describing the performance of a hypothermic perfusion platform for donor organ preservation and the ability to monitor donor organ viability.
PurThread Technologies, an award-winning developer of antimicrobial textile technology, is proud to announce the launch of its new online store. The store offers scrubs and lab coats integrated with a proprietary antimicrobial agent that protects fabrics from the damaging effects of microbial contamination.
Trovagene, Inc. announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen.
The first time Miriam Lipton had breast cancer, her thick locks fell out two weeks after starting chemotherapy. The second time breast cancer struck, Lipton gave her scalp a deep chill and kept much of her hair — making her fight for survival seem a bit easier.
When someone is diagnosed with depression, patient and doctor often begin a long trial-and-error of different treatments. Sometimes they work, sometimes they don’t, so patients may try several options before finding the best one. But in the future, a brain scan, blood test, or some combination could help guide doctors to the best drugs, or lead them to suggest talk therapy.
Stryker said an unexpected, $170 million hit related to its recalled Rejuvenate hip implant pushed its 2nd-quarter profits down nearly 35% and lowered its earnings outlook for the rest of the year. The Kalamazoo, Mich.-based medical device company posted profits of $213 million, or 56¢ per share, on sales of $2.21 billion during the 3 months ended June 30, for sales growth of 5.0% but a bottom-line slide of 34.5%.
Gamma Medica said it's closed a $16 million Series A round from Psilos Group Managers. The Northridge, Calif.-based company said it plans to use the cash to expand the commercial footprint of its LumaGen molecular breast imaging device and the LumaGuide biopsy model.
General Electric (NYSE:GE) said today that its GE Healthcare division posted 2nd-quarter profit gains despite flat sales, as the parent conglomerate beat Wall Street's earnings forecast by a penny. GE Healthcare logged profits of $726 million on sales of $4.49 billion for the 3 months ended June 30, for a bottom-line gain of 4.6% but a top-line slip of 0.2%.